Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

and rash (2.1% each). Kopetz said the global phase III, randomized KRYSTAL-10 trial has completed enrollment and will compare the combination of adagrasib and cetuximab versus FOLFIRI or mFOLFOX6 ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with ... on personalized cancer care in the context of KRAS mutation status in colorectal cancer, the clinical ...

The therapy combines Krazati (adagrasib) and cetuximab and is approved for patients ... The approved combination targets a specific mutation in the KRAS gene, known as G12C. This mutation is ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations. “The ...